Abstract：
OBJECTIVE: The current review aims to summarize the international experience of the impact of adaptive radiotherapy on dosimetry and clinical and toxicity outcomes. Additionally, it might trigger Radiation Oncologists to use ART and evaluate whether ART improves target volume coverage and/or normal tissue sparing and, consequently, therapeutic results.
METHODS: We conducted an electronic literature search of PubMed/MEDLINE and ScienceDirect from January 2007 to January 2023. The search adhered to the PRISMA guidelines and employed keywords such as ART, HNC, parotid gland, and target volume. Furthermore, we examined the reference lists for studies pertinent to the present review. This study included both retrospective and prospective studies that were considered for inclusion.
CONCLUSIONS: ART replanning appears to be a sustainable strategy to minimize toxicity by improving normal tissue sparing. Furthermore, it can enhance target volume coverage by correctly determining the specific dose to be delivered to the tumor. In conclusion, this review confirmed that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.
METHODS: We conducted an electronic literature search of PubMed/MEDLINE and ScienceDirect from January 2007 to January 2023. The search adhered to the PRISMA guidelines and employed keywords such as ART, HNC, parotid gland, and target volume. Furthermore, we examined the reference lists for studies pertinent to the present review. This study included both retrospective and prospective studies that were considered for inclusion.
CONCLUSIONS: ART replanning appears to be a sustainable strategy to minimize toxicity by improving normal tissue sparing. Furthermore, it can enhance target volume coverage by correctly determining the specific dose to be delivered to the tumor. In conclusion, this review confirmed that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.
摘要：
目的：本综述旨在总结适应性放疗对剂量学以及临床和毒性结局的影响的国际经验。此外,它可能会触发放射肿瘤学家使用ART，并评估ART是否改善目标体积覆盖率和/或保留正常组织，因此,治疗结果。
方法：我们从2007年1月至2023年1月对PubMed/MEDLINE和ScienceDirect进行了电子文献检索。搜索遵循PRISMA指南，并采用了ART等关键字，HNC,腮腺,和目标体积。此外，我们检查了与本综述相关的研究的参考文献列表.这项研究包括考虑纳入的回顾性研究和前瞻性研究。
结论：ART重新计划似乎是一种可持续的策略，通过改善正常组织的保留来最小化毒性。此外，它可以通过正确确定要递送到肿瘤的特定剂量来增强靶体积覆盖率。总之,这篇综述证实，ART对剂量学有益，临床/治疗，和毒性结果。
方法：我们从2007年1月至2023年1月对PubMed/MEDLINE和ScienceDirect进行了电子文献检索。搜索遵循PRISMA指南，并采用了ART等关键字，HNC,腮腺,和目标体积。此外，我们检查了与本综述相关的研究的参考文献列表.这项研究包括考虑纳入的回顾性研究和前瞻性研究。
结论：ART重新计划似乎是一种可持续的策略，通过改善正常组织的保留来最小化毒性。此外，它可以通过正确确定要递送到肿瘤的特定剂量来增强靶体积覆盖率。总之,这篇综述证实，ART对剂量学有益，临床/治疗，和毒性结果。
